WO2003047567A1 - STABILE, SAURE, WÄSSRIGE LÖSUNG ENTHALTEND α-LIPONSÄURE(-DERIVATE), VERFAHREN ZU DEREN HERSTELLUNG SOWIE IHRE VERWENDUNG - Google Patents
STABILE, SAURE, WÄSSRIGE LÖSUNG ENTHALTEND α-LIPONSÄURE(-DERIVATE), VERFAHREN ZU DEREN HERSTELLUNG SOWIE IHRE VERWENDUNG Download PDFInfo
- Publication number
- WO2003047567A1 WO2003047567A1 PCT/EP2002/013446 EP0213446W WO03047567A1 WO 2003047567 A1 WO2003047567 A1 WO 2003047567A1 EP 0213446 W EP0213446 W EP 0213446W WO 03047567 A1 WO03047567 A1 WO 03047567A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- solution
- lipoic acid
- particularly preferably
- stage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Definitions
- the subject of the present application is a stable, acidic, aqueous solution containing ⁇ -lipoic acid (derivatives), a process for its preparation and its use.
- ⁇ -Lipoic acid (thioctic acid, 1, 2-dithiolan-3-pentanoic acid) has been known as a growth factor in microorganisms for around 50 years, but it also occurs as an R- (+) enantiomer in small concentrations in higher plants and animals.
- ⁇ -Lipoic acid acts physiologically in hydrophilic and lipophilic media as a coenzyme for the oxidative decarboxylation of ⁇ -ketocarboxylic acids (e.g. pyruvic acid, ⁇ -ketoglutaric acid).
- ⁇ -Lipoic acid is also involved in the breakdown of certain amino acids as a cofactor.
- ⁇ -Lipoic acid and its associated redox partner dihydrolipoic acid also have strong antioxidative and sometimes prooxidative properties; ⁇ -lipoic acid is therefore often referred to as a "universal antioxidant".
- Racemic ⁇ -lipoic acid is approved for the treatment of liver diseases and neuropathies (eg diabetic polyneuropathy); their use as an effective inhibitor of the replication of HIV-1 viruses has been discussed (see Klin. Klischr. 1991, 69 (15), 722-724).
- the R-enantiomer of ⁇ -lipoic acid is in clinical phase II in Germany (since December 2000) and USA (since May 2001).
- Racemic ⁇ -lipoic acid comes as a pure pharmaceutical ingredient or as a food additive both as a pure solid in a mixture with other components , in solid galenical formulations as well as in ampoules or capsules, but also in Infusion solutions for use. Injection solutions of ⁇ -lipoic acid are preferably used primarily in the early stages of appropriate clinical therapy.
- a major disadvantage of racemic or enantiomerically pure ⁇ -lipoic acid is its lability to light and temperature and a general tendency to polymerize. The reason for this is the extremely easy cleavage of the characteristic disulfide bond of the strained five-membered ring in the lipophilic part of the molecule. This cleavage causes an intermolecular formation of disulfide bridges, which leads to dimeric, oligomeric and polymeric lipoic acid derivatives (DE-PS 16 17 740). This can be done under the influence of light or temperature, but also by adding suitable nucleophiles (J. Org. Chem. 1969, 34, 3131). Decomposition by oxidation is also known from the literature (J. Org. Chem.
- aqueous lipoic acid solutions which have a physiological or weakly alkaline pH.
- the aqueous solutions of the lipoic acid salt with trometamol prepared according to EP 318 891 B1 have a basic pH of 7.6 to 8.8.
- This patent quotes French and Spanish patents, according to which 1% aqueous solutions are prepared by an equimolar reaction of ⁇ -lipoic acid with amino acids, which results in a neutral pH for these solutions.
- DE-OS 10 47 991 and DS-OS 10 56 784 injectable solutions of lipoic acid salts are known which have a physiological or weakly alkaline pH.
- ⁇ -lipoic acid for example in physiologically effective concentrations as a food additive in beverages with an acidic pH of 2.5 to 4, has not been possible until now.
- the object of the present invention was therefore to provide a stable, acidic, aqueous solution containing ⁇ -lipoic acid or its derivatives, which contains the lipoic acid component both in physiologically effective concentrations and also ensures generally good compatibility and broad applicability.
- the aqueous solutions according to the invention can have considerably higher lipoic acid contents than according to the conventional solubility of ⁇ -lipoic acid in
- the preferred Liponsau component for the aqueous solutions according to the invention are racemic ⁇ -lipoic acid, enantiomerically pure R- (+) - or S - (-) - ⁇ -lipoic acid or any mixtures thereof, as well as racemic dihydrolipoic acid (6,8 -Dimercaptooctanoic acid), enantiomerically pure R - (-) - or S- (+) - dihydrolipoic acid or any mixtures thereof.
- the ⁇ -lipoic acid or dihydrolipoic acid can be used as such or in whole or in part in the form of its salts such as, for example, creatine, sodium, potassium, ammonium or ornithine lipoates in the preparation of the solution.
- the production of racemic ⁇ -lipoic acid, of enantiomerically pure or enantiomerically enriched R- (+) - or S - (-) - ⁇ -lipoic acid, of racemic dihydroliponic acid, enantiomerically pure or enantiomerically enriched R - (-) - or S- (+) dihydroliponic acid and their salts or mixtures can be carried out in a known manner.
- fractions are preferred which, based on the total weight of the aqueous solution according to the invention, are in each case between 0.01 and 10% by weight and particularly preferably between 0.2 and 5% by weight. All parts by weight given here are based on racemic or optically pure ⁇ -lipoic acid. This means that when using lipoic acid derivatives or salts, the amounts of the doses indicated correspond to those of the free lipoic acid and must therefore be adapted to the changed molecular weight. There is no loss of ⁇ -lipoic acid due to decomposition or polymerization in the context of the invention if the pH values of the solutions are within the range likewise essential to the invention, from the values between 2.0 and 5.5 and in particular between 2. 5 and 4.0 are to be regarded as preferred.
- the solution according to the invention may, in certain cases, possibly further conventional pharmaceutical Auxiliaries and / or formulation auxiliaries, such as ethanol, liquid polyethylene glycols (PEG), in particular of types 200-600, propylene glycol, butylene glycol, tetraglycol, benzyl alcohol, sorbitol, mannitol or glycerin.
- auxiliaries such as ethanol, liquid polyethylene glycols (PEG), in particular of types 200-600, propylene glycol, butylene glycol, tetraglycol, benzyl alcohol, sorbitol, mannitol or glycerin.
- a possibly necessary sterilization of the solution according to the invention is also possible in principle.
- the solutions according to the invention can also be filtered if necessary, for example using a blue band or black band filter.
- the present invention also claims a method for its production, in which
- the content of the lipoic acid component is adjusted to 0.001 to 30% by weight by dilution and / or the temperature is brought to values between -5 and 80 ° C. by tempering, and finally
- the pH of the solution from stage (b) is adjusted to between 0.0 and 6.5 using an acid.
- the stock solution is prepared in step (a) by adding ⁇ -lipoic acid or a suitable derivative and a likewise suitable base to the required amount of water.
- the order in which the individual components are added can be varied as desired. However, the addition should take place in all possible stages (a), (b) and (c) at temperatures from -5 to 80 ° C., preferably from 0 to 50 ° C. and particularly preferably from 4 to 30 ° C. Between the individual process steps of the procedure according to the invention, the respective solutions can be tempered as desired within the broad temperature limits specified.
- Brönsted and / or Lewis bases containing cationic components from the series of alkali metals (such as sodium or potassium) or alkaline earth metals (such as calcium or magnesium) are particularly suitable for preparing the stock solution of ⁇ -lipoic acid or its derivatives.
- alkali metals such as sodium or potassium
- alkaline earth metals such as calcium or magnesium
- the hydroxides, thiolates, acetates, carbonates and hydrogen carbonates are particularly suitable as anions.
- other bases can also be readily used, in which case the cationic component according to the invention should in particular come from the series iron, copper, zinc, palladium, vanadium and selenium.
- the organic cations and here preferably open-chain or cyclic ammonium compounds such as benzylammonium, diisopropylammonium, triethylammonium or cyclohexylammonium, or complex cations optionally with metallic central atoms, such as iron (III), chromium (III) or cobalt (II) and / or neutral, cationic or anionic ligands, such as water, ammonia, carbonyl, cyano or nitroso, or oxocations, such as oxovanadium (V) (VO 3 + ) or oxovanadium (IV) (VO 2 + )), are included for the aqueous ones Solutions according to the present invention are very suitable.
- aqueous solutions For the preparation of the aqueous solutions according to the invention, it is generally not necessary to prepare the stock solution by equimolar proportions of the lipoic acid component and the corresponding base. Rather, it has been shown that stock solutions with asymmetrical stoichiometries also lead to the stable, acidic, aqueous solutions according to the invention with a clear appearance and compatible properties. The decisive criterion for this is obviously not the stoichiometry between the lipoic acid component, the base and the acid, but the setting of a clear one Stock solution in step (a).
- a first solution containing 208 g ( ⁇ ) -dihydroliponic acid (1.0 mol) with 64 g of a 50% aqueous sodium hydroxide solution (0.8 mol) in 1.9 liters of water gives a clear solution which can be brought to a pH between 2.0 and 6.5 by adding acid.
- the clarity of this solution is verified by visual inspection, but it can also be carried out by means of conventional turbidity measurements relative to standard solutions which are familiar to the person skilled in the art.
- the base component in step (a) can be present in amounts of 0.1 to 5.0 molar equivalents, preferably 0.3 to 3.0 molar equivalents and particularly preferably 0.6 to 1.5 molar equivalents, in each case based on ⁇ -Liponic acid can be used.
- the pH at the end of stage (a) is 6.0 to 11.0 and particularly preferably between 6.5 and 10.5.
- the corresponding stock solution of ⁇ -lipoic acid, a derivative or a suitable precursor is prepared in step 8a) in concentrated form and diluted to the desired concentration range in step (b) in step (c), which preferably happens with water.
- the acids which can be used are, in particular, physiologically tolerated acids, for example organic or inorganic Bronsted acids such as hydrochloric acid, acetic acid, ascorbic acid and glutamic acid, as well as organic or inorganic Lewis acids, the series of which mainly include Carbon dioxide, Ca 2 + and Fe 2 + are particularly suitable.
- physiologically tolerated acids for example organic or inorganic Bronsted acids such as hydrochloric acid, acetic acid, ascorbic acid and glutamic acid, as well as organic or inorganic Lewis acids, the series of which mainly include Carbon dioxide, Ca 2 + and Fe 2 + are particularly suitable.
- complex acids in particular hexaaquoaluminum (III) [Al (H 2 O) 6 3 + ], and polymeric acids, of which polyphosphoric acid (PPA), an isopoly acid, such as heptamolybdic acid (H 6 Mo 7 O 24 ), or a heteropoly acid, such as dodecotungstophosphoric acid (H 3 [PW 12 O 40 ]), are particularly preferred.
- PPA polyphosphoric acid
- H 6 Mo 7 O 24 heptamolybdic acid
- H 3 [PW 12 O 40 ] dodecotungstophosphoric acid
- the acid forms or mixtures thereof can preferably be used in amounts of 0.1 to 5.0 molar equivalents, preferably 0.2 to 4.0 molar equivalents and particularly preferably 0.9 to 2.0 molar equivalents, in each case based on ⁇ -lipoic acid become.
- the present invention also takes into account the use of the solution according to the invention for pharmaceutical, cosmetic or dietetic purposes, in particular as part of a supplementary or combination therapy or as an infusion solution.
- the stable, acidic, aqueous solution according to the present invention in beverages which in particular have a pH of 2.0 to 5.5, preferably between 2.5 and 4.0 and particularly preferably between 3 , 0 and 3.5.
- the solution according to the invention is used for the prevention or reduction of photochemical damage and here in particular for those which are caused by solar radiation, UVA radiation, UVB radiation, X-rays, gamma radiation and mixtures thereof, and which are particularly preferred in humans or Animals occur.
- the solution according to the invention can also be used as a fiber treatment agent, in particular acting on the respective fiber material and subsequently the solvent used is particularly preferably removed by drying or spinning.
- fibers from cotton, linen, new wool, wool, natural silk, keratin, synthetic fibers or any mixtures thereof are taken into account in particular.
- the last-mentioned special purpose in connection with photochemical damage covers a particularly advantageous broad area, since in addition to the traditional pharmaceutical and cosmetic areas of application and areas of the food and food industry, for example, biotechnological areas of application also come into question, for example by adding the solution according to the invention to culture media.
- the present invention offers a convincing further development of the prior art, which is particularly positively supplemented by the additionally claimed and relatively simple production process.
- ⁇ -lipoic acid 1.0 g was added at room temperature to a solution of 0.24 g of sodium hydroxide in 98.76 g of water, a pH of 11.5 being established. The solution was heated to 40 ° C. and stirred for 30 min, then the mixture was acidified to pH 5.9 with 15% strength aqueous HCl. The content determination by HPLC showed a ⁇ -lipoic acid content of 1.07 ⁇ 0.1% by weight in the solution.
- Example 5 10 g of R- (+) - ⁇ -lipoic acid were added to a solution of 10 g of potassium hydroxide in 9980 g of water at room temperature. The clear solution was stirred for 30 min, during which a pH of 1 3.0 was established. The solution was cooled to 4 ° C. and acidified to pH 2.1 with 1 5% hydrochloric acid. The content determination showed an R- (+) - ⁇ -lipoic acid content of 0.1, 1 ⁇ 0.04% by weight in the solution.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02804200A EP1450789A1 (de) | 2001-12-03 | 2002-11-28 | STABILE, SAURE, W SSRIGE L SUNG ENTHALTEND a-LIPONS URE(-DERIVATE), VERFAHREN ZU DEREN HERSTELLUNG SOWIE IHRE V ERWENDUNG |
JP2005501541A JP2006502245A (ja) | 2001-12-03 | 2002-11-28 | α−リポ酸(誘導体)を含有している安定な酸性水溶液、その製造方法並びにその使用 |
US10/495,600 US20040266858A1 (en) | 2001-12-03 | 2002-11-28 | Stable, acid, aqueous solution containing alpha-liponic acid (derivatives), method for the production thereof and use of the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10159245.0 | 2001-12-03 | ||
DE10159245A DE10159245A1 (de) | 2001-12-03 | 2001-12-03 | Stabile, saure, wässrige Lösung enthaltend alpha-Liponsäure(-Derivate), Verfahren zu deren Herstellung sowie ihre Verwendung |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003047567A1 true WO2003047567A1 (de) | 2003-06-12 |
WO2003047567A8 WO2003047567A8 (de) | 2004-03-25 |
Family
ID=7707822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/013446 WO2003047567A1 (de) | 2001-12-03 | 2002-11-28 | STABILE, SAURE, WÄSSRIGE LÖSUNG ENTHALTEND α-LIPONSÄURE(-DERIVATE), VERFAHREN ZU DEREN HERSTELLUNG SOWIE IHRE VERWENDUNG |
Country Status (5)
Country | Link |
---|---|
US (1) | US20040266858A1 (de) |
EP (1) | EP1450789A1 (de) |
JP (1) | JP2006502245A (de) |
DE (1) | DE10159245A1 (de) |
WO (1) | WO2003047567A1 (de) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006042728A2 (de) * | 2004-10-15 | 2006-04-27 | Basf Aktiengesellschaft | Verwendung von ammoniumsalze der liponsäure zur behandlung diabetischer störungen |
JP2006169253A (ja) * | 2004-12-17 | 2006-06-29 | Wacker Chemie Ag | アルファリポ酸/シクロデキストリン複合体の製造方法及び製造された生成物 |
US7384558B2 (en) | 2004-07-26 | 2008-06-10 | Baxter International Inc. | Compositions capable of inhibiting reactive oxygen and carbonyl species |
CN1853626B (zh) * | 2005-04-29 | 2010-10-06 | 上海医药工业研究院 | 一种供注射用的硫辛酸冻干制剂 |
WO2016113679A1 (en) * | 2015-01-13 | 2016-07-21 | Lo.Li.Pharma S.R.L. | Lipoic acid for treating or preventing threatened miscarriage or preterm delivery |
CN111893759A (zh) * | 2020-07-30 | 2020-11-06 | 江苏阳光股份有限公司 | 一种精纺羊毛面料的抗静电整理工艺及精纺羊毛面料 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10318045A1 (de) * | 2003-04-17 | 2004-11-04 | Basf Ag | Stabile Ammoniumsalze der alpha-Liponsäure, ihre Herstellung und Verwendung |
JP4910428B2 (ja) * | 2006-03-02 | 2012-04-04 | 大正製薬株式会社 | 内服液剤組成物 |
JP5125146B2 (ja) * | 2006-03-02 | 2013-01-23 | 大正製薬株式会社 | 内服液剤 |
ITMI20061024A1 (it) * | 2006-05-25 | 2007-11-26 | Eurand Pharmaceuticals Ltd | Pellet a base di acido lipoico |
CN102300571A (zh) * | 2008-12-01 | 2011-12-28 | 英沃兹科医疗有限公司 | 包括肾素—血管紧张素醛固酮系统抑制剂和硫辛酸化合物的组合物,及其用于肾素—血管紧张素醛固酮系统相关病症的治疗 |
WO2012165468A1 (ja) * | 2011-05-31 | 2012-12-06 | 学校法人 聖マリアンナ医科大学 | 親油性化合物を高濃度で含有する液晶組成物の製造方法及びその方法によって製造された液晶組成物 |
US20190022059A1 (en) * | 2015-09-24 | 2019-01-24 | Encore Vision, Inc. | Lipoic acid choline ester compositions and methods to generate biocompatible ophthalmic formulations |
CN109925280B (zh) * | 2017-12-19 | 2021-06-01 | 大连中信药业股份有限公司 | 一种硫辛酸注射液及其制备方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4645830A (en) * | 1984-04-09 | 1987-02-24 | Takeda Chemical Industries | Stable composition of interleukin-2 and albumin |
EP0318891A1 (de) * | 1987-12-04 | 1989-06-07 | ASTA Medica Aktiengesellschaft | Injizierbare Lösung des Thioctsäuresalzes mit Trometamol und/oder basischen Aminosäuren |
EP0586987A1 (de) * | 1992-09-08 | 1994-03-16 | BASF Aktiengesellschaft | Verbessertes Verfahren zur Herstellung von R/S-gamma-Liponsäure oder R/S-alpha-Liponsäure |
WO1995034280A1 (en) * | 1994-06-15 | 1995-12-21 | The Procter & Gamble Company | Methods of lightening hyperpigmented regions in mammalian skin |
EP0812590A2 (de) * | 1989-11-09 | 1997-12-17 | ASTA Medica Aktiengesellschaft | Verwendung von R-Alpha-Liponsäure zur Zytoprotektion |
US5709868A (en) * | 1995-09-20 | 1998-01-20 | Perricone; Nicholas V. | Lipoic acid in topical compositions |
WO2000010408A1 (en) * | 1998-08-21 | 2000-03-02 | Muscletech Research And Development Inc. | Food supplements comprising lipoic acid and creatine and methods for their use |
WO2001012620A1 (de) * | 1999-08-14 | 2001-02-22 | Skw Trostberg Aktiengesellschaft | VERFAHREN ZUR HERSTELLUNG VON LÖSEMITTELFREIER α-LIPONSÄURE |
US6254898B1 (en) * | 2000-05-25 | 2001-07-03 | Protective Factors, Inc. | Nutraceutical composition for protection against solar radiation |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5990153A (en) * | 1997-05-05 | 1999-11-23 | Wood; John G. | Ultrasonicated α-lipoic acid solutions for attenuating microvascular injury |
KR100390630B1 (ko) * | 1999-07-02 | 2003-07-07 | 이희발 | 항 산화제를 함유한 복막투석액 |
-
2001
- 2001-12-03 DE DE10159245A patent/DE10159245A1/de not_active Withdrawn
-
2002
- 2002-11-28 US US10/495,600 patent/US20040266858A1/en not_active Abandoned
- 2002-11-28 WO PCT/EP2002/013446 patent/WO2003047567A1/de not_active Application Discontinuation
- 2002-11-28 JP JP2005501541A patent/JP2006502245A/ja active Pending
- 2002-11-28 EP EP02804200A patent/EP1450789A1/de not_active Withdrawn
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4645830A (en) * | 1984-04-09 | 1987-02-24 | Takeda Chemical Industries | Stable composition of interleukin-2 and albumin |
EP0318891A1 (de) * | 1987-12-04 | 1989-06-07 | ASTA Medica Aktiengesellschaft | Injizierbare Lösung des Thioctsäuresalzes mit Trometamol und/oder basischen Aminosäuren |
EP0812590A2 (de) * | 1989-11-09 | 1997-12-17 | ASTA Medica Aktiengesellschaft | Verwendung von R-Alpha-Liponsäure zur Zytoprotektion |
EP0586987A1 (de) * | 1992-09-08 | 1994-03-16 | BASF Aktiengesellschaft | Verbessertes Verfahren zur Herstellung von R/S-gamma-Liponsäure oder R/S-alpha-Liponsäure |
WO1995034280A1 (en) * | 1994-06-15 | 1995-12-21 | The Procter & Gamble Company | Methods of lightening hyperpigmented regions in mammalian skin |
US5709868A (en) * | 1995-09-20 | 1998-01-20 | Perricone; Nicholas V. | Lipoic acid in topical compositions |
WO2000010408A1 (en) * | 1998-08-21 | 2000-03-02 | Muscletech Research And Development Inc. | Food supplements comprising lipoic acid and creatine and methods for their use |
WO2001012620A1 (de) * | 1999-08-14 | 2001-02-22 | Skw Trostberg Aktiengesellschaft | VERFAHREN ZUR HERSTELLUNG VON LÖSEMITTELFREIER α-LIPONSÄURE |
US6254898B1 (en) * | 2000-05-25 | 2001-07-03 | Protective Factors, Inc. | Nutraceutical composition for protection against solar radiation |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7384558B2 (en) | 2004-07-26 | 2008-06-10 | Baxter International Inc. | Compositions capable of inhibiting reactive oxygen and carbonyl species |
WO2006042728A2 (de) * | 2004-10-15 | 2006-04-27 | Basf Aktiengesellschaft | Verwendung von ammoniumsalze der liponsäure zur behandlung diabetischer störungen |
WO2006042728A3 (de) * | 2004-10-15 | 2007-03-22 | Basf Ag | Verwendung von ammoniumsalze der liponsäure zur behandlung diabetischer störungen |
JP2006169253A (ja) * | 2004-12-17 | 2006-06-29 | Wacker Chemie Ag | アルファリポ酸/シクロデキストリン複合体の製造方法及び製造された生成物 |
US7737269B2 (en) | 2004-12-17 | 2010-06-15 | Wacker-Chemie Gmbh | Process for preparing an alpha-lipoic acid/cyclodextrin complex and product prepared |
US8481716B2 (en) | 2004-12-17 | 2013-07-09 | Wacker Chemie Ag | Process for preparing an alpha-lipoic acid/cyclodextrin complex and product prepared |
CN1853626B (zh) * | 2005-04-29 | 2010-10-06 | 上海医药工业研究院 | 一种供注射用的硫辛酸冻干制剂 |
WO2016113679A1 (en) * | 2015-01-13 | 2016-07-21 | Lo.Li.Pharma S.R.L. | Lipoic acid for treating or preventing threatened miscarriage or preterm delivery |
CN111893759A (zh) * | 2020-07-30 | 2020-11-06 | 江苏阳光股份有限公司 | 一种精纺羊毛面料的抗静电整理工艺及精纺羊毛面料 |
CN111893759B (zh) * | 2020-07-30 | 2023-03-24 | 江苏阳光股份有限公司 | 一种精纺羊毛面料的抗静电整理工艺及精纺羊毛面料 |
Also Published As
Publication number | Publication date |
---|---|
US20040266858A1 (en) | 2004-12-30 |
DE10159245A1 (de) | 2003-06-18 |
WO2003047567A8 (de) | 2004-03-25 |
EP1450789A1 (de) | 2004-09-01 |
JP2006502245A (ja) | 2006-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003047567A1 (de) | STABILE, SAURE, WÄSSRIGE LÖSUNG ENTHALTEND α-LIPONSÄURE(-DERIVATE), VERFAHREN ZU DEREN HERSTELLUNG SOWIE IHRE VERWENDUNG | |
EP0427247B1 (de) | Arzneimittel enthaltend als Wirkstoff R-alpha-Liponsäure oder S-alpha-Liponsäure | |
DE60300011T2 (de) | Perindoprilsalz und dieses enthaltende Arzneimittel | |
DE4218572A1 (de) | Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E | |
EP1827413A1 (de) | Verwendung von lipons[urehaltigen cyclodextrinkomplexen | |
DE19809304A1 (de) | Formulierungen mit antiviraler Wirkung | |
DE3031710A1 (de) | Salze von (+)-catechin, deren herstellung und verwendung sowie diese salze enthaltende pharmazeutische zubereitungen. | |
DE3118588C2 (de) | Verfahren zur Herstellung eines injizierbaren hochreinen Chondroitinpolysulfates, hiernach erhältliches Produkt und pharmazeutische Zusammensetzung | |
DE1617521C3 (de) | Verfahren zur Herstellung von Sulfonamid-Potentiator-Lösungen | |
EP0806955B1 (de) | Enrofloxacin-injektions- oder infusionslösungen | |
DE4220851A1 (de) | Verwendung von schwefel enthaltenden carbonsaeuren zur bekaempfung von pathophysiologisch bedingten erregungsstoerungen und von hierdurch bedingten erkrankungen sowie von allergischen erkrankungen sowie die herstellung entsprechender arzneimittel | |
DE2414273C3 (de) | N-Methyl-D-glucaminsalz von 2-(2'-Methyl-3'-trifluormethyl-anilin)-nicotinsäure, Verfahren zu seiner Herstellung und es enthaltende Arzneimittelzubereitung | |
EP0318891B1 (de) | Injizierbare Lösung des Thioctsäuresalzes mit Trometamol und/oder basischen Aminosäuren | |
EP1202983A1 (de) | Verfahren zur herstellung von lösemittelfreier alpha-liponsäure | |
DE2526596C2 (de) | Verfahren zur Abtrennung von Eisenverbindungen, die vom Hämoglobin stammen, von Globin in einer Blutsubstanzen enthaltenden Flüssigkeit | |
EP0211204A2 (de) | Verfahren zur Herstellung einer stabilen, wässrigen Fettemulsion und deren Verwendung in parenteral zu verabreichenden Gesamtnährlösungen | |
EP0949258A1 (de) | Alpha-Liponsäure in kristalliner Form | |
EP0700294B1 (de) | Injektionslösung für die intramuskuläre und subkutane verabreichung an tiere | |
EP3360539A1 (de) | Pharmazeutische formulierung | |
WO2001024795A1 (de) | α-LIPONSÄURE(-DERIVATE)ENTHALTENDE RETARDFORM | |
EP3328390B1 (de) | Lysinsalze von cholecalciferolsulfat und deren verwendung zur behandlung von vitamin d3-mangel | |
DE10045904B4 (de) | alpha-Liponsäure(-Derivate) enthaltende Retardform | |
DE2731013C2 (de) | Verfahren zur Herstellung einer wäßrigen Infusionslösung | |
DE2243777A1 (de) | Dihydrochinolinderivate, ihre verwendung und verfahren zur herstellung derselben | |
DE3237284C2 (de) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 24/2003 UNDER (81) ADD "JP" |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002804200 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10495600 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005501541 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002804200 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002804200 Country of ref document: EP |